0001104659-21-082070.txt : 20210616 0001104659-21-082070.hdr.sgml : 20210616 20210616170726 ACCESSION NUMBER: 0001104659-21-082070 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210614 FILED AS OF DATE: 20210616 DATE AS OF CHANGE: 20210616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bellemin Jean-Marc CENTRAL INDEX KEY: 0001754253 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36860 FILM NUMBER: 211022250 MAIL ADDRESS: STREET 1: C/O GRITSTONE ONCOLOGY, INC. STREET 2: 5858 HORTON STREET, SUITE 210 CITY: EMERYVILLE STATE: CA ZIP: 94608 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC. CENTRAL INDEX KEY: 0001425205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 753254381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 999 SKYWAY ROAD STREET 2: SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6502607120 MAIL ADDRESS: STREET 1: 999 SKYWAY ROAD STREET 2: SUITE 150 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Lion Biotechnologies, Inc. DATE OF NAME CHANGE: 20131015 FORMER COMPANY: FORMER CONFORMED NAME: Genesis Biopharma, Inc DATE OF NAME CHANGE: 20100319 FORMER COMPANY: FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP DATE OF NAME CHANGE: 20080128 4 1 tm2119923-4_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-14 0 0001425205 IOVANCE BIOTHERAPEUTICS, INC. IOVA 0001754253 Bellemin Jean-Marc C/O IOVANCE BIOTHERAPEUTICS, INC. 999 SKYWAY ROAD, SUITE 150 SAN CARLOS CA 94070 0 1 0 0 Chief Financial Officer Restricted Stock Units 2021-06-14 4 A 0 37700 0.00 A Common stock 37700 37700 D Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Provided the Reporting Person is still employed with the Issuer on the following dates, the restricted stock units vest as follows: (i) one-half of such shares shall vest and be settled on the one-year anniversary of the date of grant; and (ii) the remaining shares shall vest and be settled on December 31, 2022. /s/ Jean-Marc Bellemin 2021-06-16